Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendel, D. B.
Right arrow Articles by Cherrington, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendel, D. B.
Right arrow Articles by Cherrington, J. M.
Clinical Cancer Research Vol. 9, 327-337, January 2003
© 2003 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors

Determination of a Pharmacokinetic/Pharmacodynamic Relationship

Dirk B. Mendel1, A. Douglas Laird, Xiaohua Xin, Sharianne G. Louie, James G. Christensen, Guangmin Li, Randall E. Schreck, Tinya J. Abrams, Theresa J. Ngai, Leslie B. Lee, Lesley J. Murray, Jeremy Carver, Emily Chan, Katherine G. Moss, Joshua Ö. Haznedar, Juthamas Sukbuntherng, Robert A. Blake, Li Sun, Cho Tang, Todd Miller, Sheri Shirazian, Gerald McMahon and Julie M. Cherrington

Preclinical Research and Exploratory Development [D. B. M., A. D. L., X. X., S. G. L., J. G. C., G. L., R. E. S., T. J. A., T. J. N., L. B. L., L. J. M., J. C., E. C., K. G. M., J. M. C.], Biometabolism and Pharmacokinetics [J. Ö. H., J. S.], Discovery Technology [R. A. B.], and Chemistry [L. S., C. T., T. M., S. S., G. M.], SUGEN, Inc., South San Francisco, California 94080

One challenging aspect in the clinical development of molecularly targeted therapies, which represent a new and promising approach to treating cancers, has been the identification of a biologically active dose rather than a maximum tolerated dose. The goal of the present study was to identify a pharmacokinetic/pharmacodynamic relationship in preclinical models that could be used to help guide selection of a clinical dose. SU11248, a novel small molecule receptor tyrosine kinase inhibitor with direct antitumor as well as antiangiogenic activity via targeting the vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), KIT, and FLT3 receptor tyrosine kinases, was used as the pharmacological agent in these studies. In mouse xenograft models, SU11248 exhibited broad and potent antitumor activity causing regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines. To predict the target SU11248 exposure required to achieve antitumor activity in mouse xenograft models, we directly measured target phosphorylation in tumor xenografts before and after SU11248 treatment and correlated this with plasma inhibitor levels. In target modulation studies in vivo, SU11248 selectively inhibited Flk-1/KDR (VEGF receptor 2) and PDGF receptor ß phosphorylation (in a time- and dose-dependent manner) when plasma concentrations of inhibitor reached or exceeded 50–100 ng/ml. Similar results were obtained in a functional assay of VEGF-induced vascular permeability in vivo. Constant inhibition of VEGFR2 and PDGF receptor ß phosphorylation was not required for efficacy; at highly efficacious doses, inhibition was sustained for 12 h of a 24-h dosing interval. The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
M. Palmowski, J. Huppert, P. Hauff, M. Reinhardt, K. Schreiner, M. A. Socher, P. Hallscheidt, G. W. Kauffmann, W. Semmler, and F. Kiessling
Vessel Fractions in Tumor Xenografts Depicted by Flow- or Contrast-Sensitive Three-Dimensional High-Frequency Doppler Ultrasound Respond Differently to Antiangiogenic Treatment
Cancer Res., September 1, 2008; 68(17): 7042 - 7049.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. H. Kulke, H.-J. Lenz, N. J. Meropol, J. Posey, D. P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, et al.
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
J. Clin. Oncol., July 10, 2008; 26(20): 3403 - 3410.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
F. Navid, R. Christensen, P. Minkin, C. F Stewart, W. L Furman, and S. Baker
Stability of Sunitinib in Oral Suspension
Ann. Pharmacother., July 1, 2008; 42(7): 962 - 966.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. M. Hipp, N. Hilf, S. Walter, D. Werth, K. M. Brauer, M. P. Radsak, T. Weinschenk, H. Singh-Jasuja, and P. Brossart
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Blood, June 15, 2008; 111(12): 5610 - 5620.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. DePrimo, et al.
Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
J. Clin. Oncol., April 10, 2008; 26(11): 1810 - 1816.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Arnaud, N. E.C. Schartz, G. Bousquet, F. Sarandi, O. Verola, I. Madelaine, D. Kerob, and C. Lebbe
Transient Sunitinib-Induced Coma in a Patient With Fibromyxoid Sarcoma
J. Clin. Oncol., March 20, 2008; 26(9): 1569 - 1571.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Zhou, P. Guo, and J. M. Gallo
Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide
Clin. Cancer Res., March 1, 2008; 14(5): 1540 - 1549.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Socinski, S. Novello, J. R. Brahmer, R. Rosell, J. M. Sanchez, C. P. Belani, R. Govindan, J. N. Atkins, H. H. Gillenwater, C. Pallares, et al.
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 1, 2008; 26(4): 650 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
I. Tamaskar, R. Bukowski, P. Elson, A. G. Ioachimescu, L. Wood, R. Dreicer, T. Mekhail, J. Garcia, and B. I. Rini
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
Ann. Onc., February 1, 2008; 19(2): 265 - 268.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Blansfield, D. Caragacianu, H. R. Alexander III, M. A. Tangrea, S. Y. Morita, D. Lorang, P. Schafer, G. Muller, D. Stirling, R. E. Royal, et al.
Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy
Clin. Cancer Res., January 1, 2008; 14(1): 270 - 280.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. J. Costa and H. A. Drabkin
Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies
Oncologist, December 1, 2007; 12(12): 1404 - 1415.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. M. L. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
PNAS, October 23, 2007; 104(43): 17069 - 17074.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. B. Saltz, L. S. Rosen, J. L. Marshall, R. J. Belt, H. I. Hurwitz, S. G. Eckhardt, E. K. Bergsland, D. G. Haller, A. C. Lockhart, C. M. Rocha Lima, et al.
Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy
J. Clin. Oncol., October 20, 2007; 25(30): 4793 - 4799.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
S. de Bouard, P. Herlin, J. G. Christensen, E. Lemoisson, P. Gauduchon, E. Raymond, and J.-S. Guillamo
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
Neuro-oncol, October 1, 2007; 9(4): 412 - 423.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. A. M. van der Veldt, A. J. M. van den Eertwegh, K. Hoekman, F. Barkhof, and E. Boven
Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy
Ann. Onc., October 1, 2007; 18(10): 1747 - 1750.
[Full Text] [PDF]

Home page
 Ann OncolHome page
I Duran, R Salazar, O Casanovas, V Arrazubi, E Vilar, L. Siu, J Yao, and J Tabernero
New drug development in digestive neuroendocrine tumors
Ann. Onc., August 1, 2007; 18(8): 1307 - 1313.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. N. Stein and K. T. Flaherty
CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma
Clin. Cancer Res., July 1, 2007; 13(13): 3765 - 3770.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Norden-Zfoni, J. Desai, J. Manola, P. Beaudry, J. Force, R. Maki, J. Folkman, C. Bello, C. Baum, S. E. DePrimo, et al.
Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
Clin. Cancer Res., May 1, 2007; 13(9): 2643 - 2650.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
K. Friedrich, O. Janssen, and R. Hass
Meeting Report: Tumor Biology--How Signaling Processes Translate to Therapy
Sci. Signal., April 10, 2007; 2007(381): pe13 - pe13.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Giaccone
The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer
Clin. Cancer Res., April 1, 2007; 13(7): 1961 - 1970.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Q.M. Chow and S. G. Eckhardt
Sunitinib: From Rational Design to Clinical Efficacy
J. Clin. Oncol., March 1, 2007; 25(7): 884 - 896.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. D Chouhan, D. E Zamarripa, P. H Lai, C. U Oramasionwu, and J. L Grabinski
Sunitinib (Sutent(R)): A novel agent for the treatment of metastatic renal cell carcinoma
Journal of Oncology Pharmacy Practice, March 1, 2007; 13(1): 5 - 15.
[Abstract] [PDF]

Home page
 CA Cancer J ClinHome page
J. A. Garcia and B. I. Rini
Recent Progress in the Management of Advanced Renal Cell Carcinoma
CA Cancer J Clin, March 1, 2007; 57(2): 112 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. I. Rini
Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions
Clin. Cancer Res., February 15, 2007; 13(4): 1098 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli, P. Maione, F. Del Gaizo, G. Colantuoni, C. Guerriero, C. Ferrara, D. Nicolella, D. Comunale, A. De Vita, and A. Rossi
Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer
Oncologist, February 1, 2007; 12(2): 191 - 200.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. George
Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 753s - 757s.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
Blood, January 15, 2007; 109(2): 431 - 448.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S. T. Kim, et al.
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
N. Engl. J. Med., January 11, 2007; 356(2): 115 - 124.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
B. I. Rini, I. Tamaskar, P. Shaheen, R. Salas, J. Garcia, L. Wood, S. Reddy, R. Dreicer, and R. M. Bukowski
Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
J Natl Cancer Inst, January 3, 2007; 99(1): 81 - 83.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. H. Patel, R. S.V. Chadalavada, R.S.K. Chaganti, and R. J. Motzer
Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma
Clin. Cancer Res., December 15, 2006; 12(24): 7215 - 7220.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cao, J. M. Albert, L. Geng, P. S. Ivy, A. Sandler, D. H. Johnson, and B. Lu
Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor AZD2171 and Fractionated Radiotherapy in Mouse Models of Lung Cancer
Cancer Res., December 1, 2006; 66(23): 11409 - 11415.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Seandel, J. Shia, I. Linkov, R. G. Maki, C. R. Antonescu, and J. Dupont
The Activity of Sunitinib against Gastrointestinal Stromal Tumor Seems to be Distinct from Its Antiangiogenic Effects.
Clin. Cancer Res., October 15, 2006; 12(20): 6203 - 6204.
[Full Text] [PDF]

Home page
 FASEB J.Home page
C. D. Browne, E. J. Hindmarsh, and J. W. Smith
Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor
FASEB J, October 1, 2006; 20(12): 2027 - 2035.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. W. Kim, Y. S. Jo, H. S. Jung, H. K. Chung, J. H. Song, K. C. Park, S. H. Park, J. H. Hwang, S. Y. Rha, G. R. Kweon, et al.
An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4070 - 4076.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Ikezoe, C. Nishioka, T. Tasaka, Y. Yang, N. Komatsu, K. Togitani, H. P. Koeffler, and H. Taguchi
The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.
Mol. Cancer Ther., October 1, 2006; 5(10): 2522 - 2530.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Nakamura, E. Taguchi, T. Miura, A. Yamamoto, K. Takahashi, F. Bichat, N. Guilbaud, K. Hasegawa, K. Kubo, Y. Fujiwara, et al.
KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties.
Cancer Res., September 15, 2006; 66(18): 9134 - 9142.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Schoffski, H. Dumez, P. Clement, A. Hoeben, H. Prenen, P. Wolter, S. Joniau, T. Roskams, and H. Van Poppel
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
Ann. Onc., August 1, 2006; 17(8): 1185 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Patyna, A. D. Laird, D. B. Mendel, A.-M. O'Farrell, C. Liang, H. Guan, T. Vojkovsky, S. Vasile, X. Wang, J. Chen, et al.
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Mol. Cancer Ther., July 1, 2006; 5(7): 1774 - 1782.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone
Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions
Oncologist, July 1, 2006; 11(7): 753 - 764.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. J. Motzer, B. I. Rini, R. M. Bukowski, B. D. Curti, D. J. George, G. R. Hudes, B. G. Redman, K. A. Margolin, J. R. Merchan, G. Wilding, et al.
Sunitinib in patients with metastatic renal cell carcinoma.
JAMA, June 7, 2006; 295(21): 2516 - 2524.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
O. Potapova, A. D. Laird, M. A. Nannini, A. Barone, G. Li, K. G. Moss, J. M. Cherrington, and D. B. Mendel
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
Mol. Cancer Ther., May 1, 2006; 5(5): 1280 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ciomei, V. Croci, A. Ciavolella, D. Ballinari, and E. Pesenti
Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.
Clin. Cancer Res., May 1, 2006; 12(9): 2856 - 2861.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
B. W. Parcells, A. K. Ikeda, T. Simms-Waldrip, T. B. Moore, and K. M. Sakamoto
FMS-Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia
Stem Cells, May 1, 2006; 24(5): 1174 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Prenen, J. Cools, N. Mentens, C. Folens, R. Sciot, P. Schoffski, A. Van Oosterom, P. Marynen, and M. Debiec-Rychter
Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate
Clin. Cancer Res., April 15, 2006; 12(8): 2622 - 2627.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Guo, P. A. Marcotte, J. O. McCall, Y. Dai, L. J. Pease, M. R. Michaelides, S. K. Davidsen, and K. B. Glaser
Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
Mol. Cancer Ther., April 1, 2006; 5(4): 1007 - 1013.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Naumova, P. Ubezio, A. Garofalo, P. Borsotti, L. Cassis, E. Riccardi, E. Scanziani, S. A. Eccles, M. R. Bani, and R. Giavazzi
The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis.
Clin. Cancer Res., March 15, 2006; 12(6): 1839 - 1849.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Amino, Y. Ideyama, M. Yamano, S. Kuromitsu, K. Tajinda, K. Samizu, H. Hisamichi, A. Matsuhisa, K. Shirasuna, M. Kudoh, et al.
YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors
Clin. Cancer Res., March 1, 2006; 12(5): 1630 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
A. P. Hall, F. R. Westwood, and P. F. Wadsworth
Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate
Toxicol Pathol, February 1, 2006; 34(2): 131 - 147.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Garton, A. P.A. Crew, M. Franklin, A. R. Cooke, G. M. Wynne, L. Castaldo, J. Kahler, S. L. Winski, A. Franks, E. N. Brown, et al.
OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models
Cancer Res., January 15, 2006; 66(2): 1015 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. M. Stadler
New Targets, Therapies, and Toxicities: Lessons to Be Learned
J. Clin. Oncol., January 1, 2006; 24(1): 4 - 5.
[Full Text] [PDF]

Home page
 JCOHome page
S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini, et al.
Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
J. Clin. Oncol., January 1, 2006; 24(1): 25 - 35.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, M. D. Michaelson, B. G. Redman, G. R. Hudes, G. Wilding, R. A. Figlin, M. S. Ginsberg, S. T. Kim, C. M. Baum, S. E. DePrimo, et al.
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol., January 1, 2006; 24(1): 16 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Matsunaga, K. Nakamura, A. Yamamoto, E. Taguchi, H. Tsunoda, and K. Takahashi
Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window
Mol. Cancer Ther., January 1, 2006; 5(1): 80 - 88.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Arora and E. M. Scholar
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 971 - 979.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. R. Kim, A. Yudina, J. Figueiredo, W. Reichardt, D. Hu-Lowe, A. Petrovsky, H. W. Kang, D. Torres, U. Mahmood, R. Weissleder, et al.
Detection of Early Antiangiogenic Effects in Human Colon Adenocarcinoma Xenografts: In vivo Changes of Tumor Blood Volume in Response to Experimental VEGFR Tyrosine Kinase Inhibitor
Cancer Res., October 15, 2005; 65(20): 9253 - 9260.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Marzola, A. Degrassi, L. Calderan, P. Farace, E. Nicolato, C. Crescimanno, M. Sandri, A. Giusti, E. Pesenti, A. Terron, et al.
Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma
Clin. Cancer Res., August 15, 2005; 11(16): 5827 - 5832.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Cohen, R. B. Cohen, and N. J. Meropol
Targeting Signal Transduction Pathways in Colorectal Cancer--More Than Skin Deep
J. Clin. Oncol., August 10, 2005; 23(23): 5374 - 5385.
[Abstract] [Full Text] [PDF]

Home page